Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cells for severe COPD
ISRCTN78787702Phase 2Completed
- Sponsor
- Ministry of Science and Technology
- Start
- Jan 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic umbilical cord-derived mesenchymal stem cells in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Ministry of Science and Technology. Primary endpoint: Safety and clinical efficacy. Started Jan 2017; status: completed.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN78787702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78787702.